154 related articles for article (PubMed ID: 22856138)
1. [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
Mouseeva EV; Kuznetsova NR; Svirshchevskaia EV; Bovin NV; Sitnikov NC; Shavyrin AS; Beletskaia IP; Combes S; Fedorov AIu; Vodovozova EL
Biomed Khim; 2012; 58(3):326-38. PubMed ID: 22856138
[TBL] [Abstract][Full Text] [Related]
2. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
[TBL] [Abstract][Full Text] [Related]
3. Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the Sialyl Lewis X selectin ligand.
Kuznetsova NR; Stepanova EV; Peretolchina NM; Khochenkov DA; Boldyrev IA; Bovin NV; Vodovozova EL
J Drug Target; 2014 Oct; 22(3):242-250. PubMed ID: 24313904
[TBL] [Abstract][Full Text] [Related]
4. Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: biological effects on human tumor cells.
Kuznetsova NR; Svirshchevskaya EV; Sitnikov NS; Abodo L; Sutorius H; Zapke J; Velder J; Thomopoulou P; Oschkinat H; Prokop A; Schmalz HG; Fedorov AY; Vodovozova EL
Bioorg Khim; 2013; 39(5):609-18. PubMed ID: 25702420
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
Faustino C; Francisco AP; Isca VMS; Duarte N
Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
[TBL] [Abstract][Full Text] [Related]
6. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
Mirzavi F; Barati M; Vakili-Ghartavol R; Roshan MK; Mashreghi M; Soukhtanloo M; Jaafari MR
Int J Pharm; 2022 Feb; 613():121396. PubMed ID: 34942328
[TBL] [Abstract][Full Text] [Related]
8. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
[TBL] [Abstract][Full Text] [Related]
10. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.
Tretiakova D; Svirshchevskaya E; Onishchenko N; Alekseeva A; Boldyrev I; Kamyshinsky R; Natykan A; Lokhmotov A; Arantseva D; Shobolov D; Vodovozova E
Curr Drug Deliv; 2020; 17(4):312-323. PubMed ID: 32056524
[TBL] [Abstract][Full Text] [Related]
12. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Winn BA; Devkota L; Kuch B; MacDonough MT; Strecker TE; Wang Y; Shi Z; Gerberich JL; Mondal D; Ramirez AJ; Hamel E; Chaplin DJ; Davis P; Mason RP; Trawick ML; Pinney KG
J Nat Prod; 2020 Apr; 83(4):937-954. PubMed ID: 32196334
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs.
Pettit GR; Temple C; Narayanan VL; Varma R; Simpson MJ; Boyd MR; Rener GA; Bansal N
Anticancer Drug Des; 1995 Jun; 10(4):299-309. PubMed ID: 7786396
[TBL] [Abstract][Full Text] [Related]
14. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer.
Kuznetsova NR; Sevrin C; Lespineux D; Bovin NV; Vodovozova EL; Mészáros T; Szebeni J; Grandfils C
J Control Release; 2012 Jun; 160(2):394-400. PubMed ID: 22210161
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.
Pettit GR; Lippert JW
Anticancer Drug Des; 2000 Jun; 15(3):203-16. PubMed ID: 11049088
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the vascular targeting agent combretastatin a-4 prodrug on retinal neovascularization in the galactose-fed dog.
Kador PF; Blessing K; Randazzo J; Makita J; Wyman M
J Ocul Pharmacol Ther; 2007 Apr; 23(2):132-42. PubMed ID: 17444801
[TBL] [Abstract][Full Text] [Related]
17. Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma.
Alekseeva AA; Moiseeva EV; Onishchenko NR; Boldyrev IA; Singin AS; Budko AP; Shprakh ZS; Molotkovsky JG; Vodovozova EL
Int J Nanomedicine; 2017; 12():3735-3749. PubMed ID: 28553111
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
Meng J; Guo F; Xu H; Liang W; Wang C; Yang XD
Sci Rep; 2016 Mar; 6():22390. PubMed ID: 26947928
[TBL] [Abstract][Full Text] [Related]
19. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
[TBL] [Abstract][Full Text] [Related]
20. Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe(X), in a mouse mammary adenocarcinoma model.
Vodovozova EL; Moiseeva EV; Grechko GK; Gayenko GP; Nifant'ev NE; Bovin NV; Molotkovsky JG
Eur J Cancer; 2000 May; 36(7):942-9. PubMed ID: 10785601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
